In this study, we aim to elucidate the physiological defect of muscular Dnaja3 haploinsufficiency on mitochondrial dysfunction and dysregulated lipid metabolism and subsequently to find out the potential therapeutic regimen, GMI, via activating DNAJA3 to enhance mitochondrial homeostasis to rescue the risk of sarcopenic obesity. The gene discussed is DNAJA3; the disease is Obesity.